Tessera Therapeutics is a Gene & Genome Editing Platforms company founded in 2018 and based in Somerville, United States. It has raised $530M in total funding, most recently a Series C in 2022.
| Date | Stage | Amount | Valuation | Lead investors |
|---|---|---|---|---|
| Jul 19, 2022 | Series C | $300M | — | Flagship Pioneering |
No articles ingested yet for Tessera Therapeutics. Once the hourly news pipeline is live, every article the classifier tags as mentioning this company appears here with its one-line AI summary and sentiment.
Tessera's Gene Writing technology re-engineers mobile genetic elements — naturally occurring systems that copy and relocate DNA and RNA within genomes — into programmable tools for installing therapeutic genetic changes. Unlike CRISPR, which primarily cuts DNA, Gene Writers are designed to write new sequence directly, spanning single-nucleotide corrections, short insertions and deletions, and the insertion of entire genes. Tessera pairs the platform with lipid-nanoparticle delivery for in vivo administration, and has reported proof-of-concept data in non-human primates across its Gene Writing and delivery platforms.
We don't have a live feed for this company's ATS. Their careers page has every open role.
View all careers ↗